Stavroula Kyriazi1,2, David J. Collins1,
Veronica A. Morgan2, Catherine J. Simpkin2, Nandita M.
deSouza1,2
1CR-UK and EPSRC Cancer Imaging Centre,
Institute of Cancer Research, Sutton, Surrey, United Kingdom; 2Royal
Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom
Biochemical
(Ca125) monitoring of chemotherapeutic efficacy in advanced ovarian cancer
has limited sensitivity early in the course of treatment. Diffusion-Weighted
Imaging of peritoneal disease improves anatomical delineation but its role in
quantification of treatment response has not been established. This study
explores the value of Apparent Diffusion Coefficients calculated for the
entire metastatic tumour burden in identifying biochemical response to
platinum-based chemotherapy. Although pretreatment ADC values were not
predictive, an ADC increase after the first cycle of treatment was highly
indicative of chemosensitivity. ROC analysis for %ADC change after the first
cycle yielded an area under curve AUC=0.933. These findings may facilitate
individualised treatment strategies in advanced ovarian cancer.